Should CE Mark Pacemakers Require Action From Medtronic Stock Investors?

Medtronic secured European CE mark approval for its Vitalis portfolio of five next generation pacemakers tailored to conduction system pacing therapy, while also pushing structural cost reductions through SKU rationalization, manufacturing efficiencies, and supply chain changes that supported gross margin in the first quarter of fiscal 2027. The combination of new cardiac devices with remote monitoring features and broad cost cutting efforts signals management focus on higher value therapies...